Cingulate Inc (CING) Stock Analysis
Verdict: AVOID
Binary Phase 3 clinical risk compounded by a 7-month cash runway and persistent earnings misses—insider support is the only support.
Investment score: 34/100
Analysis as of
Is Cingulate Inc stock worth reviewing? The TradeMates thesis
A pre-revenue biotech with a ticking clock on cash and a poor track record of meeting analyst EPS expectations.
7-factor investment score
- Valuation: 25/100 (weight 20%)
- Financial Health: 15/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 10/100 (weight 15%)
- Insider Sentiment: 75/100 (weight 10%)
- Analyst Consensus: 70/100 (weight 10%)
- Risk-Adjusted Return: 30/100 (weight 15%)
Cingulate Inc opportunities and risks
What speaks for CING
- Phase 3 CTx-1301 Data Success
What speaks against CING
- Cash Runout in < 8 Months
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| CING | n/a | 0.0x | n/a | 0.0% | 0.0% | -77.7% |
| TLPH | n/a | 27184.5x | n/a | 100.0% | -1425300.0% | -41.5% |
| LONA | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -182.5% |
| IMA | n/a | 0.0x | 0.1x | 0.0% | 0.0% | -85.8% |
| SDEV | 0.1x | 14.2x | n/a | -3.5% | 21217.7% | -25.5% |
| BSEM | n/a | n/a | n/a | 128.2% | 105.1% | 2.9% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -41.5% |
Frequently asked questions about Cingulate Inc (CING)
Is CING stock a good investment?
The TradeMates model rates Cingulate Inc as AVOID with an investment score of 34/100. A pre-revenue biotech with a ticking clock on cash and a poor track record of meeting analyst EPS expectations. This is algorithmic model output, not personal investment advice.
Is CING stock a buy?
The TradeMates model verdict for CING is AVOID with an investment score of 34/100. Treat this as a model signal to review, not a personal buy recommendation.